FLOSEAL
Choose Better Outcomes. Choose FLOSEAL.
Inadequate surgical haemostasis and uncontrolled bleeding may lead to transfusion and/or other bleeding-related complications1, worse clinical outcomes and higher hospital costs2.
During the last 20 years, FLOSEAL Haemostatic Matrix has been shown to result in better clinical and hospital resource utilisation outcomes.
Take an Active Approach to Haemostasis
FLOSEAL consists of a unique combination of patented gelatin granules and human thrombin to provide quick (2 min median time to haemostasis), effective haemostasis8. Learn more about how FLOSEAL works.
Additional Product Benefits
The Leader in Hemostasis
For certain surgical procedures, use of FLOSEAL Haemostatic Matrix is associated with shorter length of surgery3, fewer intensive care unit days4, significantly lower risks of complications, blood transfusions and surgical revisions5.
Consistent Performance
FLOSEAL has been proven to perform quickly and consistently across a range of bleeds8.
Health Economic Benefits
The use of FLOSEAL can result in improved resource utilisation outcomes and substantial Cost Savings for hospitals – up to £1.1M* per year6 and £1,706 per spinal procedure*.7
*$1 = £0.76 exchange rate as at 31.3.2022
Baxter takes safety of our products and patients very seriously. If you would like to report an adverse event with Baxter drugs (e.g. Tisseel, Artiss, …), you can contact Baxter directly: [email protected] or you can report it via authority’s website:
For Belgium: www.eenbijwerkingmelden.be or www.notifieruneffetindesirable.be
For Luxembourg: www.guichet.lu/pharmacovigilance
Any medical device product quality complaints (including medical device adverse incidents) relating to Baxter products should be sent to EMEA SHS Complaints Intake [email protected]